355 related articles for article (PubMed ID: 34531849)
1. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
3. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract][Full Text] [Related]
4. The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma.
Bai S; Wu Y; Yan Y; Kang H; Zhang J; Ma W; Gao Y; Hui B; Li R; Zhang X; Ren J
Int J Med Sci; 2020; 17(18):2917-2925. PubMed ID: 33173412
[No Abstract] [Full Text] [Related]
5. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating CD39
Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
[TBL] [Abstract][Full Text] [Related]
7. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
8. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
Liu T; Zhang M; Sun D
Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract][Full Text] [Related]
10. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
Braun DA; Street K; Burke KP; Cookmeyer DL; Denize T; Pedersen CB; Gohil SH; Schindler N; Pomerance L; Hirsch L; Bakouny Z; Hou Y; Forman J; Huang T; Li S; Cui A; Keskin DB; Steinharter J; Bouchard G; Sun M; Pimenta EM; Xu W; Mahoney KM; McGregor BA; Hirsch MS; Chang SL; Livak KJ; McDermott DF; Shukla SA; Olsen LR; Signoretti S; Sharpe AH; Irizarry RA; Choueiri TK; Wu CJ
Cancer Cell; 2021 May; 39(5):632-648.e8. PubMed ID: 33711273
[TBL] [Abstract][Full Text] [Related]
11. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
[TBL] [Abstract][Full Text] [Related]
12. Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma.
Liu L; Jin H; Dong M; Tian J; Li H; Liu Q; Chen Y; Zou Z
Apoptosis; 2022 Dec; 27(11-12):946-960. PubMed ID: 36028785
[TBL] [Abstract][Full Text] [Related]
13. Construction of immune-related risk signature for renal papillary cell carcinoma.
Wang Z; Song Q; Yang Z; Chen J; Shang J; Ju W
Cancer Med; 2019 Jan; 8(1):289-304. PubMed ID: 30516029
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma.
Liu Y; Cheng X; Xi P; Zhang Z; Sun T; Gong B
BMC Urol; 2023 Apr; 23(1):54. PubMed ID: 37004005
[TBL] [Abstract][Full Text] [Related]
15. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
16. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
17. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
[TBL] [Abstract][Full Text] [Related]
18. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
Kawashima A; Uemura M; Nonomura N
Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
Shi B; Qi J
J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
[TBL] [Abstract][Full Text] [Related]
20. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]